Bcl-x 詳細
Molecule Name
Apoptosis regulator Bcl-X
分子の別称
BCL2L1,Bcl-XL,Bcl2-L-1,BCL-XL,S,BCL2L,BCLX,BCLXL,BCLXS,Bcl-X,bcl-xS
Drug Development Progress
治験薬の数8
市販薬剤の数1
研究＆開発段階Approved
ターゲットの別称
Bcl-2-like protein 1，Bcl2-L-1，BCL2L，Apoptosis regulator Bcl-X，BCL2L1，BCL2 Like 1，Protein Phosphatase 1， Regulatory Subunit 52，BCLX，BCL-XL/S，PPP1R52，Bcl-X，bcl-X Protein，Bcl-XL，Bcl-XS
バックグランド
Bcl-2-like protein 1 (BCL2L1), is also known as Apoptosis regulator Bcl-X (Bcl-XL). BCL2L1 / Bcl-XL is a homodimer protein and belongs to the Bcl-2 family. BCL2L1 is expressed at high levels in cells that undergo a high rate of turnover, such as developing lymphocytes. BCL2L1 is a potent inhibitor of cell death. BCL2L1 Inhibits activation of caspases. BCL2L1 appears to regulate cell death by blocking the voltage-dependent anion channel (VDAC) by binding to it and preventing the release of the caspase activator, CYC1, from the mitochondrial membrane. BCL2L1 / Bcl-XL also acts as a regulator of G2 checkpoint and progression to cytokinesis during mitosis.
Bcl-x 製品リスト
You Have Viewed 0 Of 0 Results
治験薬に関する情報
| 英語名 | 研究コード | 研究開発ステージ | 会社 | 適応症 | 臨床試験 |
|---|---|---|---|---|---|
| Pelcitoclax | BM-1252; APG-1252; APG 1252 12A | Phase 2 Clinical | Jiangsu Ascentage Pharma Co Ltd | Carcinoma, Non-Small-Cell Lung; Endometrial Neoplasms; Fallopian Tube Neoplasms; Lymphoma, Extranodal NK-T-Cell; Lymphoma, Non-Hodgkin; Neuroendocrine Tumors; Ovarian Neoplasms; Peritoneal Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Primary Myelofibrosis; Small Cell Lung Carcinoma; Solid tumours | 詳細 |
| LP-118 | LP-118; NWP-0476; NWP-4-76 | Phase 2 Clinical | Guangzhou Lupeng Pharmaceutical Co Ltd, Newave Pharmaceutical Inc | Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Leukemia, Prolymphocytic, T-Cell; Lymphoma, Non-Hodgkin; Multiple Myeloma; Myelodysplastic Syndromes; Myelodysplastic-Myeloproliferative Diseases; Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Primary Myelofibrosis; Richter's Syndrome; Solid tumours | 詳細 |
| Foselutoclax | UBX-1325 | Phase 2 Clinical | Ascentage Pharma Group International | Diabetic macular oedema; Macular Degeneration | 詳細 |
| R-(-)-gossypol acetic acid | R-(-) BL-193; AT-101; NSC-726190 | Phase 2 Clinical | Jiangsu Ascentage Pharma Co Ltd, University Of Michigan | Adrenocortical Carcinoma; Brain Neoplasms; Burkitt Lymphoma; Carcinoma, Non-Small-Cell Lung; CNS Embryonal Tumor; Esophageal Neoplasms; Glioblastoma; Gliosarcoma; Hormone-Resistant Prostate Neoplasms; Laryngeal Neoplasms; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Lymphoid; Lymphoma; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Extranodal NK-T-Cell; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Large-Cell, Immunoblastic; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell, Peripheral; Lymphomatoid Granulomatosis; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prostatic Neoplasms; Small Cell Lung Carcinoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Waldenstrom Macroglobulinemia | 詳細 |
| Mirzotamab clezutoclax | ABBV-155 | Phase 1 Clinical | Abbvie Inc | Solid tumours | 詳細 |
| TQB-3142 | TQB-3142 | Phase 1 Clinical | Sino Biopharmaceutical Ltd | Neoplasms | 詳細 |
| DT-2216 | DT-2216 | Phase 1 Clinical | The University Of Texas MD Anderson Cancer Center, University Of Florida, UT Health San Antonio | Hematologic Neoplasms; Solid tumours | 詳細 |
| ABBV-637 | ABBV-637 | Phase 1 Clinical | Abbvie Inc | Carcinoma, Non-Small-Cell Lung; Solid tumours | 詳細 |
市販薬剤に関する情報
| 英語名 | 研究コード | 研究開発ステージ | 会社 | オリジナル製品名 | 最初に承認をした国 | 最初の適応症 | 最初に承認を受けた会社 | 承認された日付 | 適応症 | 臨床試験 |
|---|---|---|---|---|---|---|---|---|---|---|
| Gossypol acetic acid/Potassium Chloride/Vitamin B1/Vitamin B6 | Approved | Xi'An Beifang Medicine Co Ltd | Mainland China | Uterine Hemorrhage; Uterine Neoplasms; Endometriosis | Xi'An Beifang Medicine Co Ltd | 1988-01-01 | Endometriosis; Uterine Hemorrhage; Uterine Neoplasms | 詳細 |